Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta
On 6ix: 6ix.com/news/ultragenyx-announces-first-patient-dosed-in-pivotal-phase-2-3-clinical-study-of
Watch Ultragenyx Pharmaceutical's latest callUltragenyx Pharmaceutical (NASDAQ:RARE) Q2 2026 Earnings Call · Replay · Aug 4Read the transcript of Ultragenyx Pharmaceutical (NASDAQ:RARE) Q2 2026 Earnings CallUltragenyx Pharmaceutical Inc. on 6ix
Story so far
- GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome
- Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III
- Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Earlier from Ultragenyx Pharmaceutical
- Ultragenyx to Participate in the Cowen Health Care Conference
- Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
- Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2021 Financial Results and Corporate Update
- Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvita® in Ultragenyx Territories* And Dojolvi® Globally; Provides Pipeline Updates and 2022 Milestones
- Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare Conference
Later from Ultragenyx Pharmaceutical
- Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors
- Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report
- Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update
- Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference
- Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update
Follow Ultragenyx Pharmaceutical into a list and get an email when it puts out news.
Follow Ultragenyx Pharmaceutical